Results from Previous Trials
Cardiovascular Outcomes
| ACCELERATE | Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease | 2017 | NEJM | Primary |
| ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease a nested case-control study | 2018 | JAMA | Secondary | |
| Elevated Levels of the Neutrophil to Lymphocyte Ratio Predicts Incidence of Major Adverse Cardiovascular Events in High Risk Patients: Insights from ACCELERATE | 2018 | JACC | Secondary | |
| Gender Specific Factors Associated with Major Cardiovascular Events: Insights from ACCELERATE | 2018 | JACC | Secondary | |
| Prior Cornoary Artery Bypass Grafting and Incident Cardiovascular Events in the Setting of Contemporary Medical Therapy: Insights from ACCELERATE | 2018 | JACC | Secondary | |
| Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial | 2019 | Diab Vasc Dis Res | Secondary | |
| Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy | 2019 | CIRC | Secondary | |
| Plasma aldosterone levels are not associated with cardiovascular events among patients with high-risk vascular disease: Insights from the ACCELERATE trial | 2019 | JAHA | Secondary | |
| The role of lipoprotein (a) as a marker of residual risk in patients with diabetes and established cardiovascular disease on optimal medical therapy: a post-hoc analysis of ACCELERATE | 2019 | Diabetes Care | Secondary | |
| PRECISION | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis | 2016 | NEJM | Primary |
| Cardiorenal Risks of Celecoxib compared to Naproxen, or Ibuprofen in Arthritis Patients: A Sub-Analysis From The PRECISION trial | 2017 | EHJ | Secondary | |
| Differential Blood Pressure Effects of Ibuprofen, Naproxen and Celecoxib in Patients with Arthritis: The PRECISION - ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial | 2017 | EHJ | Secondary | |
| Gastrointestinal Events in Arthritis Patients at Increased Cardiovascular Risk Treated Chronically with Celecoxib, Naproxen or Ibuprofen: the PRECISION Randomized Controlled Trial | 2017 | Gastroenterology | Secondary | |
| The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen or Naproxen: A Secondary Analysis of the PRECISION Randomized Controlled Clinical Trial | 2017 | Am J Med | Secondary | |
| Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial | 2018 | AJG | Secondary | |
| Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen | 2018 | JACC | Secondary | |
| Gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial | 2018 | AP&T | Secondary | |
| The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: A secondary analysis of the PRECISION trial | 2018 | Rheumatology | Secondary | |
| LIGHT | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors. A Randomized Clinical Trial | 2016 | JAMA | Primary |
| VISTA-16 | Varespladib and Cardiovascular Events in Patients With an Acute Coronary SyndromeThe VISTA-16 Randomized Clinical Trial | 2014 | JAMA | Primary |
| Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. A Secondary Analysis of the VISTA-16 Trial | 2019 | JAMA | Secondary | |
| dal – Outcomes | Effects of dalcetrapib in patients with a recent acute coronary syndrome | 2012 | NEJM | Primary |
| TRACER | Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes | 2012 | NEJM | Primary |
Thrombin Inhibition
| CHOOSE - ON | Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial | 2014 | Ann Thorac Surg | Primary |
Atherosclerosis Progression
| SATURN | Effect of two intensive statin regimens on progression of coronary disease | 2011 | NEJM | Primary |
| Factors underlying regression of coronary atheroma with potent statin therapy | 2013 | EHJ | Secondary | |
| Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN | 2014 | EHJ | Secondary | |
| Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN | 2017 | Atherosclerosis | Secondary | |
| Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN | 2017 | Atherosclerosis | Secondary | |
| GLAGOV | Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsThe GLAGOV Randomized Clinical Trial | 2016 | JAMA | Primary |
| Effect of Evolocumab on Coronary Plaque Composition | 2018 | JACC | Secondary | |
| Elevated CRP Levels do not Adversely Modulate the Ability of Evolucumab to Regress Coronary Atherosclerosis: Insights from GLAGOV | 2018 | JACC | Secondary | |
| Greater Likelihood of Regression of Coronary Atherosclerosis with the PCSK9 Inhibitor, Evolcumab, in Patients with Higher Lp(a) Levels | 2018 | JACC | Secondary | |
| Levels of Non-High-Density Lipoprotein Cholesterol do not Negatively Impact the Ability of the PCSK9 Inhibitor, Evolucumab, to Promote Regression of Coronary Atherosclerosis | 2018 | JACC | Secondary | |
| Sex-Related Difference in the Regression of Coronary Atherosclerosis with the PCSK9 Inhibitor, Evolucumab: Insights from GLAGOV | 2018 | JACC | Secondary | |
| GAUSS-3 | Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceThe GAUSS-3 Randomized Clinical Trial | 2016 | JAMA | Primary |
| ASSURE | Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial | 2015 | Am J Card Drugs | Primary |
| MILANO PILOT | Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein a-i milano on coronary disease in patients with an acute coronary syndrome in the milano-pilot trial: A randomized clinical trial | 2018 | JAMA | Primary |
| EAIF | Effects of the CETP Inhibitor Evacetrapib Administered asMonotherapy or inCombination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial | 2011 | JAMA | Primary |
| CARAT | Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial | 2018 | JAMA | Primary |
Diabetes
| ALECARDIO | Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial | 2014 | JAMA | Primary |
| STAMPEDE | Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes | 2012 | NEJM | Primary |
| STAMPEDE | Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 3-Year Outcomes | 2014 | NEJM | Primary |
| STAMPEDE | Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes | 2017 | NEJM | Primary |
| Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes | 2013 | Diabetes Care | Secondary | |
| Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy | 2013 | Int J Obesity | Secondary | |
| Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes | 2015 | Diabetes Care | Secondary | |
| Two‐year outcomes on bone density and fracture incidence in patients with T2DM randomized to bariatric surgery versus intensive medical therapy | 2015 | Obesity | Secondary | |
| Impact of Weight Loss Trajectory Following Randomization to Bariatric Surgery on Long-Term Diabetes Glycemic and Cardiometabolic Parameters | 2019 | Endocrine Practice | Secondary |
Heart Failure
| ASCEND-HF | Effect of Nesiritide in Patients with Acute Decompensated Heart Failure | 2011 | NEJM | Primary |
| VALOR-HCM | Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy | 2022 | JACC | Primary |
Device
| WRAP-IT | Antibacterial Envelope to Prevent Cardiac Implantable Device Infection | 2019 | NEJM | Primary |
| PARTNER 2A | Outcomes in 937 Intermediate-Risk Patients Undergoing Surgical Aortic Valve Replacement in PARTNER 2A | 2017 | ATS | Primary |
| The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA | 2018 | EHJ | Secondary | |
| Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Cardiac Surgery in the Randomized PARTNER 2A Trial | 2018 | JACC | Secondary | |
| Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis | 2016 | Lancet | Secondary | |
| Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Results From the PARTNER 2 Trial | 2018 | CIRC | Secondary | |
| Inter- and intrasite variability of mortality and stroke for sites performing both surgical and transcatheter aortic valve replacement for aortic valve stenosis in intermediate-risk patients | 2019 | JTCS | Secondary |
Acute Myocardial Infarction
| PROTECTION AMI | Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial | 2014 | EHJ | Primary |
| Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction | 2015 | AHJ | Secondary | |
| AEGIS-1 | Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I) | 2016 | CIRC | Primary |
